The Latest Breaking News from Merck

During times of uncertainty, an investor can use a covered call to deliver downside protection while capturing upside gains. Here’s how it works.

While effective vaccines for COVID-19 should have heralded the benefits of mRNA vaccines, fear and misinformation about their supposed dangers circulated at the same time. These misconceptions about mRNA vaccines have recently spilled over into worries about whether their use in agricultural animals could expose people to components of the…

The long-term prospects of Merck (MRK) look bright due to its latest acquisitions and solid drug pipeline. Therefore, investing in this stock could help generate substantial returns in the long run. Keep reading….

What you need to know… The S&P 500 Index ($SPX ) (SPY ) Monday closed up +0.33%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.30%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.06%. Stock indexes Monday posted moderate gains. An increase in...

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.11%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.23%. U.S. stock indexes this morning are mixed. An increase...

Morning Markets June S&P 500 futures (ESM2 3) this morning are up +0.02%, and June Nasdaq 100 E-Mini futures (NQM2 3) are down -0.03%. U.S. stock index futures this morning are mixed. An increase in M&A activity is positive for stocks after Merck said it would acquire Prometheus Biosciences for...

Adding a personalized cancer vaccine to the blockbuster drug Keytruda kept more melanoma patients in remission than the immune therapy alone, co-developers Moderna Inc. and Merck & Co. said in their first detailed presentation of a key study.

Earth’s gravity makes it harder to cultivate the proteins needed to study diseases and pathogens. And although the cost of space travel is high, private enterprise is stepping in

An era of gray zone warfare and sabotage creates tough financial questions.

WASHINGTON - US pharmaceutical giant Pfizer announced Monday that it had reached a deal to buy biotech firm Seagen, specializing in innovative cancer treatment, for $43 billion.

Barely a month goes by without headlines announcing yet another advancement in cancer vaccines.